Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jun
04
Today In Oncology
Online Patient Resources About AI and Cancer Found Lacking
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in Early Breast Cancer
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo